Plasma lipid profile comparison of five different cancers by nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry

Gwang Bin Lee, Jong Cheol Lee, Myeong Hee Moon

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A comprehensive lipidomic analysis at the molecular level using nanoflow ultrahigh performance liquid chromatography-electrospray ionization-tandem mass spectrometry (nUHPLC-ESI-MS/MS) was performed to elucidate the lipid profiles of patient blood samples from five commonly found cancers (liver, lung, gastric, colorectal, and thyroid), which were then compared with the lipid profiles of healthy controls. From a total of 335 lipids identified and quantified, 50 high abundance lipids showing significant changes (>2-fold and p < 0.01) in at least one of the five cancers (vs. controls) were analysed. Lipid species were found to be significantly associated with more than one type of cancer; the numbers of lipid species found as significantly changed in all five, four, three, two, and one type of cancer were 1, 8, 8, 15, and 17, respectively. Among these, the high abundance phosphatidylethanolamine species, including lysophosphatidylethanolamine and PE plasmalogen, was significantly low in four cancer types, but was high in thyroid cancer. Receiver operating characteristic analysis resulted in the selection of lipids specific to each cancer: liver (four phosphatidylinositols and diacylglycerol 16:1_18:0), gastric (phosphatidylcholine 34:2, 36:3, and 36:4, and lysophosphatidic acid 18:2), lung (lysophosphatidylinositol 16:0, sphingomyelin d18:1/20:0, and triacylglyceride 50:1 and 54:4), and thyroid (lysophosphatidylinositol 18:0 and 18:1). Our results provide a basis for future validation of cancer-specific lipid markers with high diagnostic ability.

Original languageEnglish
Pages (from-to)117-126
Number of pages10
JournalAnalytica Chimica Acta
Volume1063
DOIs
Publication statusPublished - 2019 Jul 31

Fingerprint

Liquid chromatography
Tandem Mass Spectrometry
Liquid Chromatography
Mass spectrometry
liquid chromatography
cancer
mass spectrometry
lipid
Lipids
Plasmas
plasma
Neoplasms
Liver Neoplasms
Liver
Stomach
Thyroid Gland
Plasmalogens
Electrospray ionization
Sphingomyelins
Electrospray Ionization Mass Spectrometry

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Biochemistry
  • Environmental Chemistry
  • Spectroscopy

Cite this

@article{97cc94962a9e4414a4284f6dfc509829,
title = "Plasma lipid profile comparison of five different cancers by nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry",
abstract = "A comprehensive lipidomic analysis at the molecular level using nanoflow ultrahigh performance liquid chromatography-electrospray ionization-tandem mass spectrometry (nUHPLC-ESI-MS/MS) was performed to elucidate the lipid profiles of patient blood samples from five commonly found cancers (liver, lung, gastric, colorectal, and thyroid), which were then compared with the lipid profiles of healthy controls. From a total of 335 lipids identified and quantified, 50 high abundance lipids showing significant changes (>2-fold and p < 0.01) in at least one of the five cancers (vs. controls) were analysed. Lipid species were found to be significantly associated with more than one type of cancer; the numbers of lipid species found as significantly changed in all five, four, three, two, and one type of cancer were 1, 8, 8, 15, and 17, respectively. Among these, the high abundance phosphatidylethanolamine species, including lysophosphatidylethanolamine and PE plasmalogen, was significantly low in four cancer types, but was high in thyroid cancer. Receiver operating characteristic analysis resulted in the selection of lipids specific to each cancer: liver (four phosphatidylinositols and diacylglycerol 16:1_18:0), gastric (phosphatidylcholine 34:2, 36:3, and 36:4, and lysophosphatidic acid 18:2), lung (lysophosphatidylinositol 16:0, sphingomyelin d18:1/20:0, and triacylglyceride 50:1 and 54:4), and thyroid (lysophosphatidylinositol 18:0 and 18:1). Our results provide a basis for future validation of cancer-specific lipid markers with high diagnostic ability.",
author = "Lee, {Gwang Bin} and Lee, {Jong Cheol} and Moon, {Myeong Hee}",
year = "2019",
month = "7",
day = "31",
doi = "10.1016/j.aca.2019.02.021",
language = "English",
volume = "1063",
pages = "117--126",
journal = "Analytica Chimica Acta",
issn = "0003-2670",
publisher = "Elsevier",

}

Plasma lipid profile comparison of five different cancers by nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry. / Lee, Gwang Bin; Lee, Jong Cheol; Moon, Myeong Hee.

In: Analytica Chimica Acta, Vol. 1063, 31.07.2019, p. 117-126.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Plasma lipid profile comparison of five different cancers by nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry

AU - Lee, Gwang Bin

AU - Lee, Jong Cheol

AU - Moon, Myeong Hee

PY - 2019/7/31

Y1 - 2019/7/31

N2 - A comprehensive lipidomic analysis at the molecular level using nanoflow ultrahigh performance liquid chromatography-electrospray ionization-tandem mass spectrometry (nUHPLC-ESI-MS/MS) was performed to elucidate the lipid profiles of patient blood samples from five commonly found cancers (liver, lung, gastric, colorectal, and thyroid), which were then compared with the lipid profiles of healthy controls. From a total of 335 lipids identified and quantified, 50 high abundance lipids showing significant changes (>2-fold and p < 0.01) in at least one of the five cancers (vs. controls) were analysed. Lipid species were found to be significantly associated with more than one type of cancer; the numbers of lipid species found as significantly changed in all five, four, three, two, and one type of cancer were 1, 8, 8, 15, and 17, respectively. Among these, the high abundance phosphatidylethanolamine species, including lysophosphatidylethanolamine and PE plasmalogen, was significantly low in four cancer types, but was high in thyroid cancer. Receiver operating characteristic analysis resulted in the selection of lipids specific to each cancer: liver (four phosphatidylinositols and diacylglycerol 16:1_18:0), gastric (phosphatidylcholine 34:2, 36:3, and 36:4, and lysophosphatidic acid 18:2), lung (lysophosphatidylinositol 16:0, sphingomyelin d18:1/20:0, and triacylglyceride 50:1 and 54:4), and thyroid (lysophosphatidylinositol 18:0 and 18:1). Our results provide a basis for future validation of cancer-specific lipid markers with high diagnostic ability.

AB - A comprehensive lipidomic analysis at the molecular level using nanoflow ultrahigh performance liquid chromatography-electrospray ionization-tandem mass spectrometry (nUHPLC-ESI-MS/MS) was performed to elucidate the lipid profiles of patient blood samples from five commonly found cancers (liver, lung, gastric, colorectal, and thyroid), which were then compared with the lipid profiles of healthy controls. From a total of 335 lipids identified and quantified, 50 high abundance lipids showing significant changes (>2-fold and p < 0.01) in at least one of the five cancers (vs. controls) were analysed. Lipid species were found to be significantly associated with more than one type of cancer; the numbers of lipid species found as significantly changed in all five, four, three, two, and one type of cancer were 1, 8, 8, 15, and 17, respectively. Among these, the high abundance phosphatidylethanolamine species, including lysophosphatidylethanolamine and PE plasmalogen, was significantly low in four cancer types, but was high in thyroid cancer. Receiver operating characteristic analysis resulted in the selection of lipids specific to each cancer: liver (four phosphatidylinositols and diacylglycerol 16:1_18:0), gastric (phosphatidylcholine 34:2, 36:3, and 36:4, and lysophosphatidic acid 18:2), lung (lysophosphatidylinositol 16:0, sphingomyelin d18:1/20:0, and triacylglyceride 50:1 and 54:4), and thyroid (lysophosphatidylinositol 18:0 and 18:1). Our results provide a basis for future validation of cancer-specific lipid markers with high diagnostic ability.

UR - http://www.scopus.com/inward/record.url?scp=85062002045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062002045&partnerID=8YFLogxK

U2 - 10.1016/j.aca.2019.02.021

DO - 10.1016/j.aca.2019.02.021

M3 - Article

C2 - 30967175

AN - SCOPUS:85062002045

VL - 1063

SP - 117

EP - 126

JO - Analytica Chimica Acta

JF - Analytica Chimica Acta

SN - 0003-2670

ER -